Breaking AI & Tech News Analyzed

Dates Become the New Go‑To Snack in the UKConsumers looking for a natural sweet treat are reaching for medjool dates instead of traditional biscuits or chocolate bars. The shift is being fueled by viral social‑media recipes, heightened awareness of fibre intake, and a desire for alternatives to ultra‑processed foods.Nichola Ludlam‑Raine, author of *How Not to Eat Ultra‑Processed* and spokesperson for the British Dietetic Association, describes the phenomenon as a rise in “whole food indulgence”. Dates offer a caramel‑like texture plus nutrients such as fibre, potassium, magnesium and antioxidants that support gut health.Sales and Search Metrics Show Double‑Digit GrowthOcado reports a 100% year‑on‑year increase in medjool date sales.Google searches for “date butter” have jumped 458% and for “chocolate dates” 135%.Waitrose sees a 60% rise in queries for its no‑bake Medjool date, pretzel and peanut butter squares.Recipe trends on TikTok feature dates stuffed with salted butter, sticky fried dates drizzled with olive oil, and energy balls blended with nuts, oats and plant‑based protein.What the Rise of Dates Means for the Ultra‑Processed Snack SectorThe surge signals a consumer pivot toward snacks perceived as more natural and nutrient‑dense. While dates are still treats, their higher fibre and micronutrient profile positions them as a healthier alternative, challenging the dominance of conventional confectionery and protein bars laden with additives.Supermarkets are responding by expanding date‑based product lines, and niche brands like Ayesha Erkin’s “date girl” offerings are gaining visibility, highlighting cultural ties (e.g., Ramadan) and culinary versatility.Where the Natural Sweet Snack Trend Is HeadedAnalysts expect the momentum to continue as health‑conscious shoppers seek convenient, whole‑food snacks. Potential developments include:Broader retail assortments of premium date varieties (e.g., Ajwa from Saudi Arabia, Sukkari from Morocco).Increased collaboration between snack manufacturers and dietitians to formulate “better‑for‑you” date‑based products.Continued growth in online recipe communities driving seasonal spikes, especially around Ramadan and holiday periods.Ultimately, the market will likely see a gradual reallocation of shelf space from traditional ultra‑processed sweets to natural fruit‑based options, reshaping the snack landscape over the next few years.

Executive Summary: Google Refutes Alleged Online Safety BreachGoogle says it has not broken the UK Online Safety Act despite a £950,000 fine imposed on the forum’s US operator and evidence that the site remains reachable via search results and VPNs. The controversy centers on a nihilistic suicide forum linked to 164 UK deaths, prompting calls for tighter blocking measures.Regulatory Context and the Contested Search ListingThe UK internet regulator, Ofcom, fined the forum’s operator for allowing access to content that presents a "material risk of significant harm". Although the site claims to restrict UK users voluntarily, a Google search result still displays the forum as the second entry beneath a link to the Samaritans, enabling users to bypass the block with basic software or VPNs.Key Figures and Financial Penalties£950,000 – fine levied on the forum’s US‑based operator.164 – reported UK deaths associated with the forum.2023 – year the Online Safety Act was enacted.Implications for Online Safety Governance in the UKThe case highlights tension between search engine obligations to mitigate harmful content and the principle of information access. Advocacy groups such as the Molly Rose Foundation and Families and Survivors to Prevent Online Suicide Harms argue that Ofcom’s current enforcement is insufficient, urging court orders to compel internet service providers to block the site entirely.Future Outlook: Potential Legal and Technical MeasuresOfcom is preparing an application to seek a court order that would force ISPs to cut connections to the forum if compliance is not achieved. Google maintains it will implement any formal court orders and highlights its safety features, including a prominent help box with resources like the Samaritans. The next steps will likely involve legal rulings that define the extent of search‑engine liability under the Online Safety Act.

Iran is experiencing the longest nationwide internet blackout ever recorded, according to the global monitoring group NetBlocks. Since the United States and Israel launched their war on Iran on February 28, connectivity has hovered at about 1% of pre‑war levels, effectively cutting the country off from the global web. The blackout follows a prior 20‑day shutdown in January, which coincided with deadly nationwide protests. Combined, these measures mean that Iranian civilians have spent close to two‑thirds of 2026 in digital darkness, relying only on a slow, state‑controlled intranet for basic services and state‑run news. NetBlocks highlighted that while regions such as Myanmar, Sudan, Kashmir and Tigray have endured longer intermittent outages, no other war has forced an entire nation offline to this extent. The monitor added that Iran is the first country to lose previously functional internet connectivity by reverting to a national network. Economic analysts warned that the January shutdown already caused the economy to lose tens of millions of dollars each day in direct damages, with far‑reaching indirect effects. Companies reported that many online businesses could not survive more than three weeks without connectivity, leading to a wave of layoffs and reduced pay raises. One affected worker, Kamran, a product designer in Karaj, said he was dismissed after the latest wave of cuts. He now relies on a local skill‑matching group, but fears competition from thousands of similarly displaced workers. A senior data analyst from a Tehran firm disclosed that the firm is offering lower-than‑expected raises and shifting to three‑month contracts, creating uncertainty about future employment. Compounding the digital crisis, the war has targeted Iran’s steel factories, petrochemical plants and other civilian infrastructure, aggravating pre‑existing problems of high inflation and unemployment. Only a limited segment of the population can access the global internet—either because they are whitelisted by the state or because they pay steep fees for proxy connections that often disappear after a few hours. Government spokeswoman Fatemeh Mohajerani stated that internet access is being granted only to those who can “get the voice out,” such as officials, state‑affiliated entities and news agencies. Citizens on the ground describe a grim reality: frequent power outages, uncertainty about water supplies, and an inability to use services like Google Search or AI tools, even as they watch live feeds from space missions that remain inaccessible. In response to the prolonged shutdown, authorities have begun rolling out a tiered system dubbed “Internet Pro.” Business groups have received a “guide to connect to international internet,” urging them to contact a state‑run messaging app, Bale, for registration. Parallel efforts by a major telecom carrier offer one‑year data packages at prices higher than normal plans, while existing providers have not refunded customers for services they cannot deliver. President Masoud Pezeshkian’s administration, which campaigned on unblocking Iran’s internet, has offered no official explanation for the shutdown, leaving both the battered digital sector and the broader economy facing an uncertain future.

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.